🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT06671184
Recruiting Observational

Nomogram for Predicting Difficult Transoral and Submental Thyroidectomy

NCT06671184 · tracked via the Priya Life Science China tracker
Phase
Observational
Started
2021-01-01
Last updated
2026-05-07

Condition(s) studied

Differentiated Thyroid Cancer

Investigational drug(s) / intervention(s)

Observations on clinicopathological factors influencing the difficulty of surgery

Observations on clinicopathological factors influencing the difficulty of surgery: Age, body mass index, gender, thyroid function parameters, lesion size, lesion location, ultrasound data

Study summary

No prior studies have stratified the difficulty of transoral and submental thyroidectomy (TOaST). The investigators aimed to investigate preoperative factors as indicators of difficult TOaSTs and to develop a predictive model accordingly.

Eligibility

Sex
ALL
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Clinical diagnosis of differentiated thyroid cancer with a maximum diameter not exceeding 4 cm * Absence of suspicious lateral lymph nodes or distant metastases * Participants with high cosmetic expectations * Participants who underwent total thyroidectomy and central lymph node dissection. Exclusion Criteria: * Participants with fusion or fixation of lymph nodes in the neck * Participants with history of neck surgery or radiation * Participants with vocal fold fixation by preoperative fibrolaryngoscope * Participants with preoperative examination suggestive of extrathyroidal invasion * Participants with a significantly restricted neck

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Shanghai Sixth People's Hospital Shanghai Shanghai Municipality Recruiting

More Shanghai 6th People's Hospital trials in China

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06671184 on ClinicalTrials.gov ↗ ← All trials in China